Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 12/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3761077 | 0.86 | NPC1 (0.52) | NPC1RAB9AFAAHCNR2 | |
| SCHEMBL3768360 | 0.84 | NPC1 (0.70) | NPC1RAB9AFAAH | |
| SCHEMBL928414 | 0.81 | NPC1 (0.54) | NPC1RAB9AUSP30FAAHCNR2 | |
| SCHEMBL28515199 | 0.78 | GPR119 (0.55) | ABCB1USP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL20129677 | 0.78 | GPR119 (0.55) | ABCB1USP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL20129676 | 0.78 | GPR119 (0.55) | ABCB1USP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL8104274 | 0.77 | GPR119 (0.58) | NPC1RAB9AABCB1USP30SMARCA2 | |
| SCHEMBL27711569 | 0.77 | NPC1 (0.60) | NPC1RAB9AUSP30FAAHCNR2 | |
| SCHEMBL16933528 | 0.76 | ABCB1 (0.56) | ABCB1USP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL16933529 | 0.76 | ABCB1 (0.56) | ABCB1USP30SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| CN-101103007-A | Amide compound | TAKEDA PHARMACEUTICAL (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | NPC1 1078/4885RAB9A 1416/4885ABCB1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.